U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING<br>REJECTION OVER A "PRIOR" PATENT   | Docket Number (Optional)<br>22064-71990  |
|--|--|
| In re Application of: Koppel et al.  |  |
| Application No.: 10/620,221  |  |
| Filed: 15 July 2003  |  |
| For: NEUROTHERAPEUTIC CLAVULANATE COMPOSITION AND METHOD   |  |
| The owner', Revaax Pharmaceuticals LLC of 100 percent interest in except as provided below, the terminal part of the statutory term of any patent granted on the inbeyond the expiration date of the full statutory term prior patent Nos. 6627625;6610681; 642 defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shorten hereby agrees that any patent so granted on the instant application shall be enforceable only prior patent are commonly owned. This agreement runs with any patent granted on the instanted in the instant | 6342 as the term of said prior patent is<br>d by any terminal disclaimer. The owner<br>or and during such period that it and the |
| in making the above disclaimer, the owner does not disclaim the terminal part of the ten application that would extend to the expiration date of the full statutory term as defined in 35 t "as the term of said prior patent is presently shortened by any terminal disclaimer," in the every expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutority disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate; is reissued; or   | J.S.C. 154 and 173 of the prior patent,<br>it that said prior patent later:  |
| Check either box 1 or 2 below, if appropriate.   |  |
| For submissions on behalf of a business/organization (e.g., corporation, partnership the undersigned is empowered to act on behalf of the business/organization.   | , university, government agency, etc.),  |
| I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willtid alse statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Tille 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.   |  |
| The undersigned is an attorney or agent of record. Reg. No. 48351  |  |
| -a Sayla   | August 7, 2009   |
| Signature  | Date   |
| Kevin L. McLaren   |  |
| Typed or printed name  |  |
|  | 317-231-7776   |
|  | Telephone Number   |
| Terminal disclaimer fee under 37 CFR 1.20(d) included.   |  |
| WARNING: Information on this form may become public. Credit card info  | rmation should not   |

Form PTO/SB/96 may be used for making this certification. See MPEP § 324. This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete. Rockeling gatherings, prepayings, and submitting the completed application form to the USFTO Time with very depending upon the complete the complete the complete than the complete that the complete than the complete that the complete than the complete that the complete than the complete that the complete that the complete that the complete that the complete

be included on this form. Provide credit card information and authorization on PTO-2038.

\* Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).